Next Article in Journal
Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study
Next Article in Special Issue
Acinetobacter baumannii under Acidic Conditions Induces Colistin Resistance through PmrAB Activation and Lipid A Modification
Previous Article in Journal
Optimization of Veterinary Antimicrobial Treatment in Companion and Food Animals
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy

by
Bernardetta Segatore
1,
Alessandra Piccirilli
1,
Sabrina Cherubini
1,
Luigi Principe
2,*,
Giovanni Alloggia
1,
Maria Lina Mezzatesta
3,
Mario Salmeri
3,
Stefano Di Bella
4,
Roberta Migliavacca
5,
Aurora Piazza
5,
Elisa Meroni
6,
Paolo Fazii
7,
Daniela Visaggio
8,9,
Paolo Visca
8,9,
Venere Cortazzo
10,
Giulia De Angelis
10,
Arianna Pompilio
11,12 and
Mariagrazia Perilli
1
1
Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, Italy
2
Clinical Pathology and Microbiology Unit, “S. Giovanni di Dio” Hospital, 88900 Crotone, Italy
3
Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95131 Catania, Italy
4
Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34129 Trieste, Italy
5
Unit of Microbiology and Clinical Microbiology, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy
6
Clinical Microbiology and Virology Unit, “A. Manzoni” Hospital, 23900 Lecco, Italy
7
Clinical Microbiology and Virology Unit, Spirito Santo Hospital, 65122 Pescara, Italy
8
Department of Science, Roma Tre University, Viale G. Marconi 446, 00146 Rome, Italy
9
Santa Lucia Foundation IRCCS, 00179 Rome, Italy
10
Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
11
Department of Medical, Oral and Biotechnological Sciences, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy
12
Center of Advanced Studies and Technology (CAST), “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy
*
Author to whom correspondence should be addressed.
Antibiotics 2022, 11(8), 1136; https://doi.org/10.3390/antibiotics11081136
Submission received: 2 August 2022 / Revised: 18 August 2022 / Accepted: 19 August 2022 / Published: 22 August 2022
(This article belongs to the Special Issue Antibiotic Resistance of Acinetobacter baumannii)

Abstract

In the present study, the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories. Over half (54.6%) of these isolates were resistant to colistin. The SUL–DUR combination was active against these CRAb isolates with MIC50 and MIC90 values of 0.5 mg/L and 4 mg/L, respectively. Only eleven isolates were resistant to SUL–DUR with MIC values ranging from 8 to 128 mg/L. The SUL–DUR resistant A. baumannii exhibited several antimicrobial resistance genes (ARGs) such as blaOXA-20, blaOXA-58, blaOXA-66, blaADC-25, aac(6′)-Ib3 and aac(6′)-Ib-cr and mutations in gyrA (S81L) and parC (V104I, D105E). However, in these isolates, mutations Q488K and Y528H were found in PBP3. Different determinants were also identified in these CRAb isolates, including adeABC, adeFGH, adeIJK, abeS, abaQ and abaR, which encode multidrug efflux pumps associated with resistance to multiple antibacterial agents. This is the first report on the antimicrobial activity of SUL–DUR against carbapenem-resistant A. baumannii isolates selected from multiple regions in Italy.
Keywords: durlobactam; A. baumannii; WGS durlobactam; A. baumannii; WGS

Share and Cite

MDPI and ACS Style

Segatore, B.; Piccirilli, A.; Cherubini, S.; Principe, L.; Alloggia, G.; Mezzatesta, M.L.; Salmeri, M.; Di Bella, S.; Migliavacca, R.; Piazza, A.; et al. In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy. Antibiotics 2022, 11, 1136. https://doi.org/10.3390/antibiotics11081136

AMA Style

Segatore B, Piccirilli A, Cherubini S, Principe L, Alloggia G, Mezzatesta ML, Salmeri M, Di Bella S, Migliavacca R, Piazza A, et al. In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy. Antibiotics. 2022; 11(8):1136. https://doi.org/10.3390/antibiotics11081136

Chicago/Turabian Style

Segatore, Bernardetta, Alessandra Piccirilli, Sabrina Cherubini, Luigi Principe, Giovanni Alloggia, Maria Lina Mezzatesta, Mario Salmeri, Stefano Di Bella, Roberta Migliavacca, Aurora Piazza, and et al. 2022. "In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy" Antibiotics 11, no. 8: 1136. https://doi.org/10.3390/antibiotics11081136

APA Style

Segatore, B., Piccirilli, A., Cherubini, S., Principe, L., Alloggia, G., Mezzatesta, M. L., Salmeri, M., Di Bella, S., Migliavacca, R., Piazza, A., Meroni, E., Fazii, P., Visaggio, D., Visca, P., Cortazzo, V., De Angelis, G., Pompilio, A., & Perilli, M. (2022). In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy. Antibiotics, 11(8), 1136. https://doi.org/10.3390/antibiotics11081136

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop